Role of N6-Methyladenosine RNA Modification in Cardiovascular Disease

Dandan Song; Jianhua Hou; Junduo Wu; Junnan Wang

doi:10.3389/fcvm.2021.659628

Role of N⁶-Methyladenosine RNA Modification in Cardiovascular Disease

Front Cardiovasc Med. 2021 May 7:8:659628. doi: 10.3389/fcvm.2021.659628. eCollection 2021.

Authors

Dandan Song^{1

2}, Jianhua Hou³, Junduo Wu⁴, Junnan Wang⁴

Affiliations

¹ Department of Clinical Laboratory, Second Hospital of Jilin University, Changchun, China.
² State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, College of Chemistry, Jilin University, Changchun, China.
³ Department of Orthodontics, Hospital of Stomatology, Jilin University, Changchun, China.
⁴ Department of Cardiology, Second Hospital of Jilin University, Changchun, China.

Abstract

Despite treatments being improved and many risk factors being identified, cardiovascular disease (CVD) is still a leading cause of mortality and disability worldwide. N⁶-methyladenosine (m⁶A) is the most common, abundant, and conserved internal modification in RNAs and plays an important role in the development of CVD. Many studies have shown that aabnormal m⁶A modifications of coding RNAs are involved in the development of CVD. In addition, non-coding RNAs (ncRNAs) exert post-transcriptional regulation in many diseases including CVD. Although ncRNAs have also been found to be modified by m⁶A, the studies on m⁶A modifications of ncRNAs in CVD are currently lacking. In this review, we summarized the recent progress in understanding m⁶A modifications in the context of coding RNAs and ncRNAs, as well as their regulatory roles in CVD.

Keywords: CVD; M6A; mRNAs; modification; non-coding RNAs.

Publication types

Review